StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX – Free Report) in a research note released on Wednesday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.
Separately, Stifel Nicolaus reaffirmed a hold rating and set a $2.00 target price on shares of IRIDEX in a research note on Wednesday, May 15th.
Get Our Latest Analysis on IRIDEX
IRIDEX Stock Performance
IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). IRIDEX had a negative net margin of 21.92% and a negative return on equity of 105.42%. The firm had revenue of $12.63 million for the quarter, compared to the consensus estimate of $12.80 million. During the same period in the prior year, the business earned ($0.17) EPS. On average, equities research analysts predict that IRIDEX will post -0.49 EPS for the current year.
Institutional Investors Weigh In On IRIDEX
A hedge fund recently raised its stake in IRIDEX stock. AMH Equity Ltd grew its stake in shares of IRIDEX Co. (NASDAQ:IRIX – Free Report) by 15.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 456,400 shares of the medical equipment provider’s stock after purchasing an additional 60,400 shares during the period. IRIDEX comprises about 1.3% of AMH Equity Ltd’s holdings, making the stock its 20th biggest holding. AMH Equity Ltd owned 2.81% of IRIDEX worth $1,360,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 20.10% of the company’s stock.
About IRIDEX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Featured Stories
- Five stocks we like better than IRIDEX
- What Are Dividend Contenders? Investing in Dividend Contenders
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Market Cap Calculator: How to Calculate Market Cap
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.